Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.58 |
| ▸ | NPY4R | P50391 | 9/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.55 |
| ▸ | NPY1R | P25929 | 6/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | TFPI | P10646 | 1/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508108 | 0.93 | NPY4R (0.57) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16508111 | 0.90 | TFPI (0.62) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16508143 | 0.90 | TFPI (0.62) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16509136 | 0.90 | NPY4R (0.52) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16507868 | 0.89 | NPY4R (0.58) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30442285 | 0.88 | KISS1R (0.59) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16508093 | 0.87 | TFPI (0.63) | KISS1RNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16508074 | 0.86 | IL23R (0.55) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL16507955 | 0.86 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30967723 | 0.86 | KISS1R (0.57) | KISS1RTFPIIL23RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | KISS1R 571/4885NPY4R 1387/4885NPY5R 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.